An interventional study of Exercise in Ocular Melanoma, sponsored by University of Valencia. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.
Sponsored by University of Valencia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Uveal Melanoma with a site in Spain — 4 open to participants now, 11 under way, 4 of them phase 3. Uveal Melanoma · Spain.
Among the 22 studies in Uveal Melanoma with a site in Spain, this one is the 16th largest by planned enrollment, is one of 2 that started in 2025, is the only one with no phase, reaches primary completion later than 3 of the 10 other live ones, and was the 21st registered.
281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.
Browse Uveal Melanoma studies →4 of the 22 studies in Uveal Melanoma with a site in Spain are open now. Recruiting first, the newest first:
IDEAYA Biosciences · Sites in Spain, United States, Australia and 18 more countries
Ages 18+
European Organisation for Research and Treatment of Cancer - EORTC · Sites in Spain, United States, Belgium and 6 more countries
Ages 18+
MonTa Biosciences ApS · Sites in Spain, Denmark
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 43 Uveal Melanoma studies recruiting now, 36 (84%) set no upper age limit and 4 (9%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 12 · Phase 3 6
First in 2013; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 37 across 222 interventional studies indexed under Uveal Melanoma.
Median enrollment 94 across the 22 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 10 most frequent:
University of Valencia is the lead sponsor of 357 studies on the registry; 75 are open to participants now.
University of Valencia has 1 study filed under Uveal Melanoma — fewer than ten, so there is no comparison to draw.
5 of the studies in Uveal Melanoma with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT06007690Phase 3Aura BiosciencesA Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | 2027-11-15 |
| NCT06970236University of ValenciaResistance Exercise in Patients With Ocular Melanoma | 2026-12 |
| NCT04855435MonTa Biosciences ApSSafety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours | 2027-03 |
| NCT05415072Novartis PharmaceuticalsA Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 22 studies in Uveal Melanoma with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Choroidal melanoma (CM) is one of the most common intraocular cancers worldwide. During treatment with episcleral brachytherapy, patients require a week of hospitalization in isolation. The primary aim of this study will be to investigate the effects of resistance training during hospitalization on health-related blood biomarkers in CM patients. Our secondary aim will be to assess changes in physical function tests, quality of life and anxiety and depression. Candidates for this study will be patients undergoing CM treatment at the "Hospital Universitari i Politècnic La Fe" of Valencia.
Candidates of the present study will be adults with CM diagnose and treated with plaque brachytherapy undergoing in "Hospital Universitari i Politècnic La Fe" (Valencia). All the participants will be informed about the objectives and content of the investigation and written informed consent will be obtained. Participants will be excluded if they (1) present a health status that forbids high intensity resistance training, (2) have any unsteady cardiac illness, (3) have serious metabolic disorder or if (4) they have any important orthopaedic disorder impeding exercise. The study will conform to the Declaration of Helsinki and will be approved by the Ethical Committee of "Hospital Universitari i Politècnic de La Fe".
A randomized controlled trial with two parallel groups is planned: a control group following the hospital's standard protocol (usual care) and an intervention group in which patients will complete a daily resistance training session during hospitalization. During the 5-7 days of treatment, where participants are going to be isolated in a room without human contact, are going to perform a daily session of exercise during about 30 minutes. The exercises will be supervised by a trained physician. To carry out the training session, elastic resistance bands will be used. On each day, each exercise will start with 3 sets of two repetitions as a warm-up and to calculate the appropriate intensity. The intensity will be that at which the patient reports a perceived exertion of 5-6 of 10 at the Borg CR10 scale after two repetitions. For each exercise, one set will be completed until task failure is achieved.If in any of the exercises the patient perceives this intensity only with the weight of his own limb or body weight, the exercise will be performed without elastic bands.
To observe the effects of the intervention, various blood tests, functional, quality-of-life and anxiety and depression assessments will be conducted before and after the program, as well as one-month post-hospital discharge.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants on this group will follow the exercise intervention mentioned in the protocol.
Other: Exercise
Patients in the control group will follow the hospital's conventional protocol during the hospitalization days, which consists in isolated bed rest.
Daily session during hospitalization. To carry out the training session, elastic bands (TheraBand CLX Consecutive Loops; TheraBand, Akron, OH) with resistance graded from very low to very high (i.e, yellow, red, green, blue, black, silver and gold) will be used. On each day, each exercise will start with 3 sets of two repetitions as a warm-up and to calculate the appropriate intensity. The intensity will be that at which the patient reports a perceived exertion of 5-6 of 10 at the Borg CR10 scale after two repetitions. For each exercise, one set will be completed until task failure is achieved.If in any of the exercises the patient perceives this intensity only with the weight of his own limb or body weight, the exercise will be performed without elastic bands.
Blood biomarkers: glucose
Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: urea
Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: creatinine
Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: glomerular filtration
Metabolic and lipidic response marker measured in milliliters/minutes/1,73 (ml/min/1,73).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: total bilirubin
Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: aspartate aminotransferase
Metabolic and lipidic response marker measured in units/liter (U/L).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: alanine aminotransferase
Metabolic and lipidic response marker measured in units/liter (U/L).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: alkaline phosphatase
Metabolic and lipidic response marker measured in units/liter (U/L).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: lactate dehydrogenase
Metabolic and lipidic response marker measured in units/liter (U/L).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: creatine kinase
Metabolic and lipidic response marker measured in units/liter (U/L).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: total proteins
Metabolic and lipidic response marker measured in grams/deciliter (g/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: albumin
Metabolic and lipidic response marker measured in grams/deciliter (g/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: C-reactive protein
Inflammatory response marker measured in milligrams/liter (mg/L).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: interleukin 6
Inflammatory response marker measured in picograms/milliliter (pg/ml).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: calcium
Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: albumine-corrected calcium
Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: chloride
Metabolic and lipidic response marker measured in milliequivalents/liter (mEq/L).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: sodium
Metabolic and lipidic response marker measured in milliequivalents/liter (mEq/L).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: potassium
Metabolic and lipidic response marker measured in milliequivalents/liter (mEq/L).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: total cholesterol
Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: HDL cholesterol
Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: LDL cholesterol
Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: no HDL cholesterol
Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: triglycerides
Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: hematies
Blood marker measured in x10\^6/microliter (x10\^6/µL).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: hemoglobin
Blood marker measured in grams/deciliter (g/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: hematocrit
Blood marker measured in percentage (%).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: mean corpuscular volume
Blood marker measured in femtoliters (fL).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: mean corpuscular hemoglobine
Blood marker measured in picograms (pg).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: mean corpuscular hemoglobin concentration
Blood marker measured in grams/deciliter (g/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: red cell distribution width - standard deviation
Blood marker measured in femtoliters (fL).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: red cell distribution width - coefficient of variation
Blood marker measured in percentage (%).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: erythroblasts
Blood marker measured in percentage (%).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: leukocytes
Blood marker measured in x10\^3/microliter (x10\^3/µL).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: neutrophils
Blood marker measured in x10\^3/microliter (x10\^3/µL).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: lymphocytes
Blood marker measured in x10\^3/microliter (x10\^3/µL).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: monocytes
Blood marker measured in x10\^3/microliter (x10\^3/µL).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: eosinophils
Blood marker measured in x10\^3/microliter (x10\^3/µL).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: basophils
Blood marker measured in x10\^3/microliter (x10\^3/µL).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: neutrophils %
Blood marker measured in percentage (%).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: lymphocytes %
Blood marker measured in percentage (%).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: monocytes %
Blood marker measured in percentage (%).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: eosinophils %
Blood marker measured in percentage (%).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: basophils %
Blood marker measured in percentage (%).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: immature granulocytes %
Blood marker measured in percentage (%).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: platelets
Blood marker measured in x10\^3/microliter (x10\^3/µL).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: mean platelet volume
Blood marker measured in femtoliters (fL).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: platelet distribution width
Blood marker measured in femtoliters (fL).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: platelet large cell ratio
Blood marker measured in percentage (%).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: prothrombin time
Blood marker measured in seconds (sec).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: prothrombin time ratio
Blood marker.
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: Quick index
Blood marker measured in percentage (%).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: activated partial thromboplastin time
Blood marker measured in seconds (sec).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: activated partial thromboplastin time ratio
Blood marker.
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: derived fibrinogen
Blood marker measured in milligrams/deciliter (mg/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: procalcitonin
Inflammatory response markers measured in nanograms/milliliter (ng/ml).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: glycated hemoblobin A1c
Metabolic and lipidic response marker measured in percentage (%).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: estimated average glucose
Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: carcinoembryonic antigen
Tumor marker measured in nanograms per milliliter (ng/ml).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Blood biomarkers: S-100
Tumor markers measured in micrograms per liter (µg/L).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
EORTC_C30
The patient self-reported outcomes comprised the EORTC_ C30 questionnaire. This survey assesses various dimensions of quality of life.
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
EORTC_OPT30
The patient self-reported outcomes comprised also the complementary EORTC_ OPT30 module specifically designed for patients with eye cancer. This survey assesses various dimensions of quality of life, and the OPT30 module has a particular focus on evaluating visual functioning limitations.
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
HADS questionnaire
The Hospital Anxiety and Depression Scale (HADS) will be used to measure symptoms of anxiety (HADS Anxiety) and depression (HADS Depression).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Physical activity levels
The patients will be also asked about their levels of physical activity prior to hospitalization (minutes/week during the last month).
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
TUG test
To evaluate agility/coordination, the timed-up-and-go-test (TUG) will be used to, which consists of rising from a chair on command, walking a distance of 3 m, turning around, and walking back to the chair as fast as possible.
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
30s StS Test
To assess muscle strength of lower limbs (endurance strength), the patient will be performed the 30-s sit-to-stand test (30 s StS), which is to stand up and sit down as many times as possible in 30 s.
Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.